Pharmaceutical - Financial, AbbVie

Filter

Current filters:

FinancialAbbVie

Popular Filters

AbbVie raises expectations driven by strong performance

AbbVie raises expectations driven by strong performance

24-06-2014

US drugmaker AbbVie has raised the midpoint of its full-year 2014 earnings-per-share guidance by six…

AbbVieAmortizationBusiness FinanceFinanceFinancialGuidancePharmaceuticalUSAUSD

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland

03-06-2014

The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…

AbbVieAnti-viralsFinancialIrelandPharmaceuticalProduction

AbbVie beats forecasts, as Humira sales keep soaring

25-04-2014

US drugmaker AbbVie, now in its second year as an independent spin-out for Abbott, pleased investors…

AbbVieFinancialPharmaceutical

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

AbbVie sees profits downturn but meets analysts’ expectations

AbbVie sees profits downturn but meets analysts’ expectations

01-02-2014

US drugmaker AbbVie’s shares gained 3% to $49.77 in morning trading on January 31, when the company…

AbbVieFinancialPharmaceutical

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

27-10-2013

Shares of AbbVie were up 2.4% at $49.09 in afternoon trading on the New York Stock Exchange on Friday,…

AbbVieFinancialHumiraPharmaceutical

Yaroslavl region of Russia to become major center for the country’s pharmaceutical production

Yaroslavl region of Russia to become major center for the country’s pharmaceutical production

05-10-2013

The Russian Yaroslavl region is expected to become one of the major centers of the country’s pharmaceutical…

AbbVieCadila PharmaceuticalsEuropeFinancialPharmaceuticalProductionTakeda PharmaceuticalsTeva Pharmaceutical Industries

AbbVie beats expectations, as Humira keeps growing

28-07-2013

US drugmaker AbbVie (NYSE: ABBV), spun-out from Abbott Laboratories from the start of this year, reported…

AbbVieFinancialHumiraPharmaceutical

Abbott sales rise 2.5% in 2nd quarter, but profits plunge

17-07-2013

US health care company Abbott Laboratories (NYSE: ABT), which split out its research-based prescription…

AbbVieFinancialNorth AmericaPharmaceutical

Strong 1st-qtr for AbbVie, as Humira continues to grow

28-04-2013

Shares in US drugmaker AbbVie (NYSE: ABBV) rose 3.6% to $45.84 on Friday, when the company posted first-quarter…

AbbVieFinancialPharmaceutical

AbbVie inaugural full-year outlook for 2013 in line with expectations

31-01-2013

Newly spun-out from Abbott Labs, research-based pharma company AbbVie (NYSE: ABB) yesterday confirmed…

Abbott LaboratoriesAbbVieFinancialPharmaceuticalResearch

Abbott board prepares way for AbbVie split off

29-11-2012

US health care giant Abbott Laboratories (NYSE: ABT) says that its board of directors has approved the…

Abbott LaboratoriesAbbVieFinancialPharmaceutical

Abbott Labs' AbbVie bond deal hit $37 billion yesterday, sources report

06-11-2012

US health care major Abbott Laboratories (NYSE: ABT) and its subsidiary AbbVie came to market early Monday…

Abbott LaboratoriesAbbVieFinancialPharmaceutical

Back to top